| 
Results for primecell therapeutics. Search took 0.06 seconds.
Google to Invest in Biotechnology
in The Biotech Weblog, on April 2, 2009
...in View, Calif.
Google is open to funding biotechnology start-ups. "If we find an interesting therapeutics company, we'd be happy to put down a term sheet," Maris said.
Read the entire...
Nominations Open for the Biotech Humanitarian Award
in The Biotech Weblog, on January 13, 2009
...r, philanthropist or educator - whose work in biotechnology made significant impact in the areas of therapeutics, food and agriculture, or industrial or environmental applications.
Qualified nominees...
Nanotubes Punching Holes in Cancer
in Nanotechbuzz, on August 28, 2008
...icity, and more effective treatment of cancer. The future of cancer care will involve more targeted therapeutics on molecular and nano-mechanical levels. Source: Stanford News
...
Instantly Stop Bleeding
in Nanotechbuzz, on May 28, 2008
...certain individuals who have bleeding disorders such as hemophilia .
A company called Arch Therapeutics has licensed special technology from MIT and is developing a material that may instant...
Top Ten Cool Hedge Fund Moves
in The Hedge Funds Weblog, on January 4, 2008
...ipotle Mexican Grill
Firm: Tremblant Capital Group
Profit: $95 million
Top Trade #10: United Therapeutics Corp.
Firm: Shunway Capital Partners
Profit: $73 million
...
More Evidence that Alzheimer's is A Type 3 Diabetes
in Daily Diabetic, on November 30, 2007
...shes, "the insulin receptors disappeared from their surfaces."
This just means that new therapeutics in both diabetes and Alzheimer's can potentially be developed in lieu of such findi...
Enhanced HIV Vaccine, Helped Monkeys Kick AIDS-like Symptoms
in Straightfromthedoc, on November 28, 2007
... Penn.:
"DNA vaccine technology has great promise for the development of vaccines and immune therapeutics for a variety of infectious diseases and cancers.
While previous studies have establis...
Cannabis Compound Can Potentially Fight Metastatic Breast Cancer
in Straightfromthedoc, on November 25, 2007
...tive it is still considered a Schedule 1 drug.
Findings appear in the journal Molecular Cancer Therapeutics .
Source: California Pacific Medical Center Research Institute (a pdf file)
...
Fish Oil, Good Supplemental Treatment for Lupus
in Straightfromthedoc, on November 13, 2007
...al function.
According to Stephen Wright, MD, specialist registrar in rheumatology, department of therapeutics and musculoskeletal education & research unit, Queen's University of Belfast, ...
Peptide Therapeutics Symposium
in The Biotech Weblog, on November 5, 2007
... What : San Diego's 2nd Annual peptide Therapeutics Symposium
When : November 10, 2007
Where : The Hilton, La Jolla Torrey Pines, CA
Internationally acclaimed speakers from will prov...
Tuberculosis Drug Candidate SQ109 Granted Orphan Drug Status
in The Biotech Weblog, on October 30, 2007
... National Cancer Institute /NIAID Inter-Institute Program for the Development of AIDS-related Therapeutics. NIAID licensed the SQ109 technology to Sequella in March 2006 under a Cooperative Rese...
Flavopiridol and Cisplatin Combination May Be Effective Against Platinum-Resistant Ovarian Cancer
in The Biotech Weblog, on October 25, 2007
...py using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resi...
Tea Helps Strengthen Hips
in Well Woman Blog, on October 16, 2007
...otentially helpful," said Paul Brandt, an associate professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine. "One or two cups of te...
Alzheimer's Disease: Type 3 Diabetes?
in Daily Diabetic, on September 27, 2007
...
This fundamental connection between the two conditions offers hope for the development of future therapeutics.
Source: Science Daily ; FASEBJ Abstract
...
Red Wine Diet
in Celebrate Wine, on September 19, 2007
...s published by avery (326 pages, $15.95). Corder is a cardiovascular expert and professor of therapeutics at London's William Harvey Research Institute....
Human Source of Stem Cells With Potential To Repair Muscle Damaged by Disease or Injury
in The Biotech Weblog, on September 5, 2007
Scientists have isolated stem cells from blood vessels (known as myoendothelial cells) which can be differentiated in the laboratory into muscle, bone and cartilage cells and are thus suitable for use as a potential therapy for muscle injuries and diseases including heart attack and muscle dystro...
Symposium: Regulatory RNA in Biology and Human Health
in The Biotech Weblog, on August 28, 2007
...and biogenesis of small regulatory RNAs and how this is being applied to create a new generation of therapeutics and diagnostics.
The main topics to be discussed in this symposium includes:
Mech...
Elixir Pharma's Type 2 Diabetes Drug Mitiglinide Enters Phase III Clinical Trial
in Daily Diabetic, on August 22, 2007
...cal Advisory Board:
"There continues to be a tremendous unmet medical need in the U.S. for therapeutics that can be used alone or in combination with other drugs to provide patients with type 2...
About Generex's Oral-Lyn™ Oral Insulin Spray
in Daily Diabetic, on August 17, 2007
...s are yielding promising results, as was recently published in Diabetes Technology & Therapeutics (article title: Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime i...
DNA Vaccine Against Multiple Scclerosis Appears Safe
in The Biotech Weblog, on August 15, 2007
...
Results of a clinical trial funded by Bayhill Therapeutics, Inc. shows that BHT-3009 , a newly developed DNA vaccine against multiple sclerosis appears safe and may produce beneficial changes...
Pollinex Quattro Hay Fever Vaccine Clinical Studies on Hold
in Allergies, on August 7, 2007
... Late last year, there were high hopes on Allergy Therapeutics ' new version of ragweed allergy vaccine called Pollinex Quattro , which has entered the last stages of development. Unlik...
Dynavax Technologies Corp. Received $30 Million for Allergy Franchise
in Allergies, on July 25, 2007
...verse immunologic response in allergic diseases.
Given the market opportunities associated with therapeutics targeting these areas, Deerfield has partnered with us in this venture and agreed to shar...
Brustvergroeßerung, natuerlich, mit Stammzellen aus eigenem Fettgewebe
in Das Gesundheits-Weblog, on July 10, 2007
...ntnommen. Aus diesem werden mit einem vom kalifornischen Biotechnologieunternehmen Cytori Therapeutics entwickelten Gerät innerhalb von nur einer Stunde Fett-Stammzellen isoliert und angereichert. Ans...
Protein May Prevent Eye Damage in Preemies
in Straightfromthedoc, on June 20, 2007
...s for retinopathy of prematurity.
According to Dr. Maria B. Grant, a professor of pharmacology and therapeutics at UF's College of Medicine:
"We've identified a protein that is part of...
PTC124 Drug Candidate Against Duchenne Muscular Dystrophy and Other Genetic Diseases
in The Biotech Weblog, on April 25, 2007
Scientists report of a new prototype drug, designed to treat Duchenne muscular dystrophy but which may be useful in the treatment of up 1800 different genetic diseases. The drug, called PTC124 , has restored muscle function in mice trials.
Normal cells assemble amino acids into protein molecu...
ADHD Children Who Start on Strattera® More Likely to Change Therapies, Study Says
in Straightfromthedoc, on April 19, 2007
...ere initially used.
Such were the results of a study conducted by pharmacy benefit manager Prime Therapeutics LLC (Prime) .
In lieu of such results, Prime has developed programs that promote the u...
Snake Venom Toxin Inhibits Human Prostate Cancer Cell Growth
in The Biotech Weblog, on April 16, 2007
... A study published in a recent issue of Molecular Cancer Therapeutics report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen -i...
Merck Licenses Coley Pharma's VaxImmune for $4 Million
in The Biotech Weblog, on April 13, 2007
... infectious disease and biowarfare applications.
Source: Coley Pharmaceutical
Photo: TLR Therapeutics, Coley Pharmaceuticals ...
Something to Watch
in The Hedge Funds Weblog, on March 30, 2007
...Interesting article here; Osiris Rises on Heart-Treatment News .
Investors bid up Osiris Therapeutics stock by 13.6% to $20.33 per share in early trading on the Nasdaq on March 26 after the company&...
Pregnancy and Back Pain
in Well Woman Blog, on March 15, 2007
... reports on a recent study:
The study, published in the Journal of Manipulative and Physiological Therapeutics, says despite the high prevalence of musculoskeletal pain during pregnancy, few women i...
Final Four
in Businesspundit, on March 13, 2007
There seems to be a canyon-wide disconnect between the ivory towers of theoretical academia and the reality of industry and commercial applications. The Institute for Technology Entrepreneurship and Commercialization (ITEC) at Boston University is aiming to bridge that gap with its 7th Annual Busin...
Novel Pulsed Microjet System for Needle-Free Delivery of Protein Drugs
in The Biotech Weblog, on March 12, 2007
...ly a 12 billion needle injections are performed every year for the delivery of vaccines and protein therapeutics such as insulin , growth hormone and erythropoietin (a red blood cell booster).
R...
Michael J. Fox to Deliver Keynote Address at 2007 BIO International Convention
in The Biotech Weblog, on March 2, 2007
....
The discussion will explore strategies and solutions to "de-risk" investment in novel therapeutics for the biotechnology industry and academia alike.
Read the full report .
...
Adipose-Derived Stem Cell Therapy for Cardiovascular Disease
in The Biotech Weblog, on February 9, 2007
...
Cytori Therapeutics , a biotech firm developing stem and regenerative cell therapies for cardiovascular diseases treated their first patient in a hospital in Spain as part of Cytori's randomi...
Chromium Picolinate: Best Chromium Form to Clinically Benefit Diabetics
in Straightfromthedoc, on February 2, 2007
...d analysis of Chromium Picolinate , published in the current edition of Diabetes Technology & Therapeutics , confirms that chromium picolinate is effective in improving glycemic control a...
Evaluating Press Releases Before Buying Biotech Stocks
in The Biotech Weblog, on January 22, 2007
...you need?
Adam Feuerstein offers valuable insights in interpreting press releases , taking Point Therapeutics ' press release as a case in point.
...
Biotechnology in 2007
in The Biotech Weblog, on January 4, 2007
...echnology. Care to make predictions? In what areas do you think we'll make big progress on? New therapeutics? Economically feasible alternative energy sources? Novel technology in agriculture and ...
Protein Biomarkers for Alzheimer's Disease
in The Biotech Weblog, on December 14, 2006
... aid in the early detection and diagnosis of AD, but also help in identifying and testing potential therapeutics.
[Image: Three-dimensional visualization of part of the spinal fluid protein bar code ...
Using RNAi Technology Against BSE and CJD
in The Biotech Weblog, on December 10, 2006
... Scientists may be on to a novel approach for the development of therapeutics against neurodegenerative diseases such as Bovine spongiform encephalopathy (BSE, also known as "mad cow dis...
Pollinex Quattro Ragweed Allergy Vaccine Enters Last Stages of Development
in Allergies, on November 24, 2006
... Allergy Therapeutics , the makers of ragweed allergy vaccine Pollinex-R , are making headway with a new version of ragweed allergy vaccine called Pollinex Quattro Ragweed. This new formulation ...
Drug Discovery Firm e-Therapeutics Screens South American Forests for Lead Compounds
in The Biotech Weblog, on November 6, 2006
...
e-Therapeutics , a spin off biotech company from Newcastle University has partnered with Brazilian company Grupo TCI to establish a joint research facility close to the Amazonian and Atlantic r...
Marijuana Component Slows Down Alzheimer's Disease
in The Biotech Weblog, on October 10, 2006
...ists say that THC may be a drug lead which may be used as a model to develop new and more effective therapeutics for Alzheimer's Disease.
The results of the study exploring the molecular link be...
3rd Annual RNAi Europe Conference and Exhibition
in The Biotech Weblog, on September 21, 2006
...igh Content RNAi Genomic Screens
RNAi Technology: From Drug Target Discovery to Validation
RNAi Therapeutics
A pre-conference half day course entitled " RNAi and
microRNA: Emerging Market ...
Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel
in The Biotech Weblog, on September 19, 2006
... Cell Therapeutics, Inc. and Novartis will collaborate to co-develop XYOTAX™ (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer ...
Smoking Reduces the Effects of Alcohol: Reason Why Smoking and Drinking is an Inseparable Tandem
in Straightfromthedoc, on July 28, 2006
... expected effect," said Wei-Jung A. Chen, associate professor of neuroscience and experimental therapeutics at The Texas A&M Health Science Center College of Medicine.
"In other words,...
Nanoparticle anti-cancer drug tested on humans
in Nanotechbuzz, on July 21, 2006
...
Insert Therapeutics has treated its first patient in a Phase I study of IT-101, its lead anti-cancer compound, says a company press release :
The study involves patients with inoperable or m...
Morgan Stanley Expect Favorable Returns from Large Biotech Companies
in The Biotech Weblog, on July 20, 2006
...,a three-in-one tablet against HIV.
and Celgene : Focuses on cancer and inflammatory disease therapeutics. Top products include Thalomid and Revlimid , both approved for the treatment of multiple...
Wellcome Trust to Issue Sterling Bonds
in The Biotech Weblog, on July 6, 2006
...mong the research thrusts of the Wellcome Trust were the human genome sequencing, developing therapeutics for malaria and psychological disorders, as well as sponsoring the National Science Lea...
Medical Genomics Laboratory in Berlin
in The Biotech Weblog, on July 5, 2006
... million research center focuses on the identification of origins of disease and search for novel therapeutics using genome research. Located within the building is the Gene Mapping Center and ...
Second Annual Meeting of the Oligonucleotide Therapeutics Society
in The Biotech Weblog, on June 27, 2006
... What : Second Annual Meeting of the Oligonucleotide Therapeutics Society
When : October 19-21, 2006
Where : Caspary Auditorium at the Rockefeller University, New York, NY
Conference will hi...
Blood Test Will Predict Success of Quitting in Smokers Using Nicotine Patch
in Straightfromthedoc, on June 15, 2006
... to the results of a study published in the June issue of the Journal of Clinical Pharmacology and Therapeutics , a blood test may enable doctors to predict which smokers using the nicotine pa...
Origen To Produce Therapeutics in Genetically Engineered Chickens
in The Biotech Weblog, on June 9, 2006
...f an anti-clotting agent in transgenic goats , other firms are tailgating. California-based Origen Therapeutics have been developing genetically modified chickens to manufacture human antibo...
Blood Test To Determine Nicotine Patch Success
in The Biotech Weblog, on May 20, 2006
...sults of the study will be published in the June issue of the Journal of Clinical Pharmacology and Therapeutics (available to subscribers).
[Photo: British Heart Foundation ]
...
Sirna Therapeutics Licenses microRNA Technology From UMMS
in The Biotech Weblog, on May 15, 2006
...
Sirna Therapeutics, Inc signed an exclusive worldwide licensing agreement for the rights to patents covering microRNA (miRNA) technology for the modulation of gene expression, developed at t...
Merck Acquires GlycoFi and Abmaxis for $480 Million
in The Biotech Weblog, on May 10, 2006
...s of a proprietal yeast glycoengineering technology that has potential use in developing novel biotherapeutics. Abmaxis , on the other hand, is a private biopharmaceutical company which optimizes a...
Pfizer Acquires Rinat Neuroscience Corp.
in The Biotech Weblog, on April 13, 2006
...and disorders of the central nervous system.
"Rinat is a pioneer in developing protein-based therapeutics and we see tremendous potential in its research to develop new medicines, notably for t...
Microbia Raises $75M To Advance IBS Drug Candidate Through Clinical Trials
in The Biotech Weblog, on February 28, 2006
...ignificant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase 1 cholesterol absorptio...
Nanotechnology in Pharmaceuticals and Biotechnology Conference
in The Biotech Weblog, on February 25, 2006
...logy and its applications in drug discovery and development, drug delivery, Diagnostics , and therapeutics. Pharma executives and management consultants will also deliver talks on commercialisat...
Chelsea Therapeutics Closes $21.5 Million Placement of Common Stocks
in The Biotech Weblog, on February 15, 2006
...
Chelsea Therapeutics International, Ltd . sold approximately 7.2 million shares of its common stock , raising about $21.5M in proceeds. Healthcor Management, LP was the lead investor in this...
New Genomic Method Enables Gene Disruption in Pathogenic Fungi
in The Biotech Weblog, on February 3, 2006
...s in humans. By understanding how fungi modulate immune responses in humans, new ways of developing therapeutics for these conditions could be identified.
Photo: Semena.org About Gloria Gamat: Gl...
Inhalable Insulin Exubera Approved By FDA
in The Biotech Weblog, on January 27, 2006
...ent of type-1 and type-2 diabetes has been developed by Pfizerwith Sanofi- Aventis and Nektar Therapeutics, and is to be marketed as "Exubera" .
"Until today, patients with diab...
Quintek to deliver services nationally to major biotechnology company with annual sales of $12 Billion
in The Outsourcing Weblog, on January 11, 2006
...otechnology company is engaged in the discovery, development, manufacturing, and marketing of human therapeutics based on advances in cellular and molecular biology. For the new agreement, Quintek wil...
Fruitfly Gut Stem Cells Similar to Human's
in The Biotech Weblog, on December 13, 2005
...at will help in understanding human digestive disorders, including some cancers, and for developing therapeutics.
Source: Carnegie Insitution News Release ...
Cephalon Acquires Rights To Psoriasis Drug Candidate
in The Biotech Weblog, on December 12, 2005
.../pharmacokinetics studies of K252a is currently being evaluated by Bio3 Research and Creabilis Therapeutics , who owns patent applications covering K252a-based products for the treatment of psori...
How cancer cells spread
in Straightfromthedoc, on December 8, 2005
...ing cancers also might help doctors prevent metastasis, wrote Patricia Steeg, director of molecular therapeutics at the US National Cancer Institute in Bethesda, Md., in a commentary accompanying the ...
New Target For Anti-Inflammatory Compounds
in The Biotech Weblog, on December 6, 2005
...be a novel target for the development of a new generation of anti-inflammatory /anti-trauma therapeutics. The structural characterization of CERK published in the December issue of the Journal...
Sirna Therapeutics Patents Vector Expressed siRNA Against Huntington's Disease
in The Biotech Weblog, on October 5, 2005
...vector expressed siRNAs targeting the Huntington's disease (HD) gene, has been issued to Sirna Therapeutics, Inc . In particular, the patent includes vector expressed siRNAs with 3' -overhang...
Chronic antibiotics and the risk of respiratory infections
in Straightfromthedoc, on September 20, 2005
...rgolis, M.D., and colleagues at the University of Pennsylvania Center for Education and Research in Therapeutics here.
"The true clinical importance of our findings, in which patients and practi...
Biotech Companies Announcing Public Offering of Common Stocks
in The Biotech Weblog, on September 19, 2005
...o sell 5,000,000 shares of newly issued common stock. GTx is a biopharmaceutical company developing therapeutics for cancer and serious conditions related to men's health, focusing on small molec...
Aerosurf: Novel Therapy Against Respiratory Distress Syndrome (RDS)
in The Biotech Weblog, on September 12, 2005
The first pilot Phase 2 feasibility study of Aerosurf, developed by Dicovery Labs , showed promising results. Aerosurf is a aerosolized lung surfactant delivered using continuous positive airway pressure (nCPAP). It has the potential as a non-invasive method of surfactant replacement therap...
